Treatment of Uterine Leiomyomata with Mifepristons
Zhong Huifang, Hu Xianglian
1996, 1(2):
118-119.
Asbtract
(
89 )
PDF (222KB)
(
161
)
References |
Related Articles |
Metrics
Aim To evaluate the effect of mifepristone on uterine leiomyomata. Methods Thirty-eight patients with leiomyomata were randomly divided into two groups, nineteen in each group. The patients in group A were prescribed nifepristone, 50 mg/day, for 3 months beginning on the first day of the menstrual cycle the subjects in group B were given tra-ditional Chinese medicine (NEI XIAO LUO LI WAN) without mifepristone. All subjects had a pelvic sonogram performed blood before initiation of therapy and monthly there-after. Beselin and monthly sannples for complete blood count, liver and renal functions and hormonal evaluation were obtained, LH,FSH, PR1.E2 and P were determined by RIA. Results Three months after receiving mifepristone, a mean reduction of 52% in leiomyomata volune was observed, the difference of the tumor volume between group A and B was statistically significant. Mifepristone was well tolerated by all patients except that two patients experienced atypical hot flashes, When compared with pretreatment values, mifepristone treatment induced a significant increase in mean LH levels (P<0.01) and decline in P and E2 (P<0.01). Conclusion Mifepristone had a therapeutic effect on uterine leiomyomata and its adverse reactions were mild.